Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 432

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 432
---
, including our ability to process
samples, provide test results, share and monitor safety data, bill payers or patients, provide customer support services, conduct research
and development activities, process and prepare company financial information, manage various general and administrative aspects of our
business and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.

Geopolitical
events and global economic conditions, such as the Israel-Hamas war may impact the third parties that we engage to supply materials or
manufacture any products for our preclinical tests and clinical trials, which increases the risk of potential delay of development efforts,
as applicable.

If
the third parties that we engage to supply any materials or manufacture any products for our preclinical tests and clinical trials should
cease to continue to do so for any reason, including due to the effects of global economic conditions, including the Hamas-Israel war,
we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers,
as applicable, and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able
to obtain adequate supplies of our product, or the substances used to manufacture them, it will be more difficult for us to develop our
product and compete effectively.

Our
current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop our product, and product candidates
and could delay our clinical trials and development programs as well as affect our marketing and commercialization efforts. In addition,
such dependence may increase our costs and expenses, and may otherwise harm our operations and financial condition

31

Risks
Related to Development and Regulatory Approval of Our Product Candidates

Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results
of clinical trials are open to differing interpretations.

Clinical
trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results
differently than us. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates
are expected to continue for several years and may take significantly longer to complete. In addition, we, the FDA, or other regulatory
authorities, including state and local authorities, or an Institutional Review Board, or IRB, with respect to a trial at its institution,
may suspend, delay or terminate our clinical trials at any time, require us to conduct